N C Patel1, J L Gallagher, T R Torgerson, A L Gilman. 1. Department of Pediatrics, Section of Infectious Disease and Immunology, Levine Children's Hospital at Carolinas Medical Center, PO Box 32861, Charlotte, NC, 28203, USA, Niraj.Patel@carolinashealthcare.org.
Abstract
PURPOSE: Autosomal dominant hyper-IgE syndrome (AD-HIES), caused by mutations in Signal Transducer and Activator of Transcription 3 (STAT3) is associated with defective STAT3 signaling and Th17 differentiation and recurrent bacterial and fungal infections. Most patients suffer significant morbidity and premature mortality. Hematopoietic stem cell transplantation (HSCT) has been reported in a small number of cases, with mixed outcomes. We report successful haploidentical donor HSCT in a patient with AD-HIES. METHODS: Evaluation of lymphocyte subsets, STAT3 signaling, and Th17 cells was performed pre- and post-HSCT. RESULTS: A 14-year old female with AD-HIES developed recurrent methicillin-resistant Staphylococcus aureus (MRSA) abscesses. Immunologic analysis showed elevated IgE (4331 kU/L), absent Th17 cells, and markedly decreased STAT3 phosphorylation in cytokine stimulated peripheral blood mononuclear cells. She had breakthrough abscesses despite clindamycin and trimethoprim-sulfamethoxazole prophylaxis, and developed steroid refractory autoimmune hemolytic anemia. She underwent T-cell depleted haploidentical HSCT from her father following reduced intensity conditioning. She developed one MRSA hand abscess after transplant. Twenty-four months post transplant, she had complete donor chimerism (>95 % donor), normal absolute T cell numbers, and a normal percentage of Th17 cells. IgE was normal at 25 kU/L. She remains well 42 months after transplantation off all antibacterial prophylaxis. CONCLUSIONS: Haploidentical HSCT led to successful bone marrow engraftment, normalization of STAT3 signaling in hematopoietic cells, normalization of IgE, and restoration of immune function in this patient with AD-HIES.
PURPOSE: Autosomal dominant hyper-IgE syndrome (AD-HIES), caused by mutations in Signal Transducer and Activator of Transcription 3 (STAT3) is associated with defective STAT3 signaling and Th17 differentiation and recurrent bacterial and fungal infections. Most patients suffer significant morbidity and premature mortality. Hematopoietic stem cell transplantation (HSCT) has been reported in a small number of cases, with mixed outcomes. We report successful haploidentical donor HSCT in a patient with AD-HIES. METHODS: Evaluation of lymphocyte subsets, STAT3 signaling, and Th17 cells was performed pre- and post-HSCT. RESULTS: A 14-year old female with AD-HIES developed recurrent methicillin-resistant Staphylococcus aureus (MRSA) abscesses. Immunologic analysis showed elevated IgE (4331 kU/L), absent Th17 cells, and markedly decreased STAT3 phosphorylation in cytokine stimulated peripheral blood mononuclear cells. She had breakthrough abscesses despite clindamycin and trimethoprim-sulfamethoxazole prophylaxis, and developed steroid refractory autoimmune hemolytic anemia. She underwent T-cell depleted haploidentical HSCT from her father following reduced intensity conditioning. She developed one MRSA hand abscess after transplant. Twenty-four months post transplant, she had complete donor chimerism (>95 % donor), normal absolute T cell numbers, and a normal percentage of Th17 cells. IgE was normal at 25 kU/L. She remains well 42 months after transplantation off all antibacterial prophylaxis. CONCLUSIONS: Haploidentical HSCT led to successful bone marrow engraftment, normalization of STAT3 signaling in hematopoietic cells, normalization of IgE, and restoration of immune function in this patient with AD-HIES.
Authors: Andrea M Siegel; Jennifer Heimall; Alexandra F Freeman; Amy P Hsu; Erica Brittain; Jason M Brenchley; Daniel C Douek; Gary H Fahle; Jeffrey I Cohen; Steven M Holland; Joshua D Milner Journal: Immunity Date: 2011-11-23 Impact factor: 31.745
Authors: Alexandra F Freeman; David E Kleiner; Hari Nadiminti; Joie Davis; Martha Quezado; Victoria Anderson; Jennifer M Puck; Steven M Holland Journal: J Allergy Clin Immunol Date: 2007-03-01 Impact factor: 10.793
Authors: Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Corey S Cutler; Nazmim S Bhuiya; Michael Schowalter; Vincent T Ho; Edwin P Alyea; John Koreth; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz Journal: Blood Date: 2009-01-23 Impact factor: 22.113
Authors: Marco Yamazaki-Nakashimada; Samuel Zaltzman-Girshevich; Silvestre Garcia de la Puente; Beatriz De Leon-Bojorge; Sara Espinosa-Padilla; Marimar Saez-de-Ocariz; Daniel Carrasco-Daza; Victor Hernandez-Bautista; Lorenzo Pérez-Fernandez; Francisco Espinosa-Rosales Journal: Pediatr Nephrol Date: 2006-06-22 Impact factor: 3.651
Authors: Claire E Bocchini; Karen Nahmod; Panagiotis Katsonis; Sang Kim; Moses M Kasembeli; Alexandra Freeman; Olivier Lichtarge; George Makedonas; David J Tweardy Journal: Blood Date: 2016-10-31 Impact factor: 22.113
Authors: Yael Gernez; Alexandra F Freeman; Steven M Holland; Elizabeth Garabedian; Niraj C Patel; Jennifer M Puck; Kathleen E Sullivan; Javeed Akhter; Elizabeth Secord; Karin Chen; Rebecca Buckley; Elie Haddad; Hans D Ochs; Ramsay Fuleihan; John Routes; Mica Muskat; Patricia Lugar; Julien Mancini; Charlotte Cunningham-Rundles Journal: J Allergy Clin Immunol Pract Date: 2017-09-19
Authors: Ian A Myles; Erik D Anderson; Noah J Earland; Kol A Zarember; Inka Sastalla; Kelli W Williams; Portia Gough; Ian N Moore; Sundar Ganesan; Cedar J Fowler; Arian Laurence; Mary Garofalo; Douglas B Kuhns; Mark D Kieh; Arhum Saleem; Pamela A Welch; Dirk A Darnell; John I Gallin; Alexandra F Freeman; Steven M Holland; Sandip K Datta Journal: J Clin Invest Date: 2018-07-23 Impact factor: 14.808
Authors: Stephanie C Harrison; Christo Tsilifis; Mary A Slatter; Zohreh Nademi; Austen Worth; Paul Veys; Mark J Ponsford; Stephen Jolles; Waleed Al-Herz; Terence Flood; Andrew J Cant; Rainer Doffinger; Gabriela Barcenas-Morales; Ben Carpenter; Rachael Hough; Ásgeir Haraldsson; Jennifer Heimall; Bodo Grimbacher; Mario Abinun; Andrew R Gennery Journal: J Clin Immunol Date: 2021-02-01 Impact factor: 8.317